vaccination Archives - Revista Brasileira de Ginecologia e Obstetrícia
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(6):602-608
, , , , The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination.
This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers.
Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible.
Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(6):602-608
, , , , The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination.
This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers.
Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible.
Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(12):926-931
, , , , , , , The present study assesses the implementation and the impact after 2 years of a school-based human papillomavirus (HPV) vaccination program in a Brazilian city.
A prospective study assessing the implementation of the program, offering quadrivalent HPV vaccine in two annual doses to girls and boys aged from 9 to 10 years old. The program was started in the city of Indaiatuba, state of São Paulo, Brazil, in 2018, and had authorization from the National Immunization Program. The number of HPV vaccine first doses applied and the coverage in 2018 was calculated and compared to the year 2017. There were described events that have influenced the results.
The program invited 4,878 children through schools (87.1% of the target population), and 7.5% refused vaccination. Several concurrent events required or competed for health professionals of the vaccination teams. The coverage of the first dose (between 9 and 10 years old) was 16.1% in 2017 and increased to 50.5% in 2018 (p < 0.0001). The first dose in all ages increased 78% in 2018 compared with 2017 (6,636/3,733). Competing demands over the program continued in 2019, and the first dose coverage dropped (26.9%). For 2020, a municipal law instituted school-based vaccination and the creation of dedicated teams for vaccination, and these strategies are waiting to be tested.
School-based annual HPV vaccination in children between 9 and 10 years old was feasible and increased vaccination coverage, regardless of gender, although the program was vulnerable to competing events.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(12):926-931
, , , , , , , The present study assesses the implementation and the impact after 2 years of a school-based human papillomavirus (HPV) vaccination program in a Brazilian city.
A prospective study assessing the implementation of the program, offering quadrivalent HPV vaccine in two annual doses to girls and boys aged from 9 to 10 years old. The program was started in the city of Indaiatuba, state of São Paulo, Brazil, in 2018, and had authorization from the National Immunization Program. The number of HPV vaccine first doses applied and the coverage in 2018 was calculated and compared to the year 2017. There were described events that have influenced the results.
The program invited 4,878 children through schools (87.1% of the target population), and 7.5% refused vaccination. Several concurrent events required or competed for health professionals of the vaccination teams. The coverage of the first dose (between 9 and 10 years old) was 16.1% in 2017 and increased to 50.5% in 2018 (p < 0.0001). The first dose in all ages increased 78% in 2018 compared with 2017 (6,636/3,733). Competing demands over the program continued in 2019, and the first dose coverage dropped (26.9%). For 2020, a municipal law instituted school-based vaccination and the creation of dedicated teams for vaccination, and these strategies are waiting to be tested.
School-based annual HPV vaccination in children between 9 and 10 years old was feasible and increased vaccination coverage, regardless of gender, although the program was vulnerable to competing events.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(8):571-576
DOI 10.1590/S0100-72032003000800005
PURPOSE: to estimate the prevalence of the hepatitis B surface antigen (HBsAg) in parturients admitted to the "Instituto Materno-Infantil de Pernambuco (IMIP)", Recife-PE, and to determine the serologic profile of the positive ones. METHODS: this is a prospective cross-sectional study where the VIDAS and VIDAS HBs systems were used for detection and confirmation of HBsAg, respectively. The parturients were randomly selected. In HBsAg+ patients, the other serologic markers were tested by the use of the AxSYM automated system. The newborn babies of HBsAg+ mothers were vaccinated with the Engerix B vaccine. RESULTS: among 1584 parturients, there were 9 (0.6%) HBsAg positive. None of them had anti-HBc IgM, thus they were all prevalent cases. In 1/9 (11.1%) of the HBsAg+ mothers, HBeAg was isolated and in 4/9 (44.4%), this antigen circulated along with its antibody, hence the importance of establishing the different magnitudes of risk of vertical transmission. Except for two newborn babies from a twin pregnancy (one with low birth weight), all presented seroconversion to anti-HBs with 3 doses of the vaccine. The premature twin babies showed seroconvertion only after the fourth dose of the vaccine. CONCLUSIONS: the prevalence of hepatitis B among parturients at IMIP is relatively low and all patients diagnosed had the chronic form of the infection.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(8):571-576
DOI 10.1590/S0100-72032003000800005
PURPOSE: to estimate the prevalence of the hepatitis B surface antigen (HBsAg) in parturients admitted to the "Instituto Materno-Infantil de Pernambuco (IMIP)", Recife-PE, and to determine the serologic profile of the positive ones. METHODS: this is a prospective cross-sectional study where the VIDAS and VIDAS HBs systems were used for detection and confirmation of HBsAg, respectively. The parturients were randomly selected. In HBsAg+ patients, the other serologic markers were tested by the use of the AxSYM automated system. The newborn babies of HBsAg+ mothers were vaccinated with the Engerix B vaccine. RESULTS: among 1584 parturients, there were 9 (0.6%) HBsAg positive. None of them had anti-HBc IgM, thus they were all prevalent cases. In 1/9 (11.1%) of the HBsAg+ mothers, HBeAg was isolated and in 4/9 (44.4%), this antigen circulated along with its antibody, hence the importance of establishing the different magnitudes of risk of vertical transmission. Except for two newborn babies from a twin pregnancy (one with low birth weight), all presented seroconversion to anti-HBs with 3 doses of the vaccine. The premature twin babies showed seroconvertion only after the fourth dose of the vaccine. CONCLUSIONS: the prevalence of hepatitis B among parturients at IMIP is relatively low and all patients diagnosed had the chronic form of the infection.